Cue biopharma to present at two february 2023 scientific conferences

Boston, feb. 01, 2023 (globe newswire) -- cue biopharma, inc. (nasdaq: cue), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific t cells directly within the patient's body, announced today that its president and chief scientific officer, anish suri, ph.d., will participate in two scientific conferences this february, the immuno-oncology 360 o summit, taking place february 7-10 in new york, ny, and the federation of american societies for experimental biology (faseb) catalyst conference, taking place virtually february 8-9, 2023.
CUE Ratings Summary
CUE Quant Ranking